| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
In an aging society, the number of people with dementia has increased. Since Alzheimer's disease and a part of frontotemporal lober degeneration (FTLD-tau) have abnormal tau pathology in brain, these are called Tauopathy. Previously results showed that abnormal tau has been involved in development of cognitive dysfunction suggesting that tau-focused drug might be valuable in therapy for Tauopathy. This study screened low molecular compounds that were targeted to tau, and obtained two evidences. First, novel compounds were identified as tau aggregation inhibitor, and inhibited tau cytotoxicity. Second, inhibitory mechanism of tau aggregation by the compounds was elucidated. These data will initiate clinical study and research for drug discovery based on the mechanism. Thus, the study provided scientific basic outcomes, which may be contributed to development of cognitive therapies for dementia.
|
